Full Press Release Details
Dupixent® (dupilumab) Showed Positive Topline Results in Two Phase 3 Trials of Patients with Chronic Rhinosinusitis with Nasal Polyps.
REGN
Dupixent® (dupilumab) Showed Positive Topline Results in Two Phase 3 Trials of Patients with Chronic Rhinosinusitis with Nasal Polyps
Key Takeaway: Dupixent® (dupilumab) Showed Positive Topline Results in Two Phase 3 Trials of Patients with Chronic Rhinosinusitis with Nasal Polyps